# EDGAR Filing Document

**Accession Number:** 0001404123
**File Stem:** 0001562180-23-001849
**Filing Date:** 2023-2
**Character Count:** 10283
**Document Hash:** 7595a1a012d031576583428ec7187f0c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001562180-23-001849.hdr.sgml**: 20230224

**ACCESSION NUMBER**: 0001562180-23-001849

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230222

**FILED AS OF DATE**: 20230224

**DATE AS OF CHANGE**: 20230224

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Kennedy David P
- **CENTRAL INDEX KEY:** 0001800529

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39203
- **FILM NUMBER:** 23668881

**MAIL ADDRESS:**
- **STREET 1:** ONE EMBARCADERO CENTER, SUITE 1900
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94111
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** 1Life Healthcare Inc
- **CENTRAL INDEX KEY:** 0001404123
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
- **IRS NUMBER:** 760707204
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** ONE EMBARCADERO CENTER, SUITE 1900
- **CITY:** San Francisco
- **STATE:** CA
- **ZIP:** 94111
- **BUSINESS PHONE:** (415) 814-0927

**MAIL ADDRESS:**
- **STREET 1:** ONE EMBARCADERO CENTER, SUITE 1900
- **CITY:** San Francisco
- **STATE:** CA
- **ZIP:** 94111

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 1life Healthcare Inc
- **DATE OF NAME CHANGE:** 20070621

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Kennedy David P<br><sub>(Last) (First) (Middle)</sub><br>C/O 1LIFE HEALTHCARE, INC.<br>ONE EMBARCADERO CENTER, SUITE 1900<br><sub>(Street)</sub><br>SAN FRANCISCO, CA 94111<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-22 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>1Life Healthcare Inc [ ONEM ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-02-22 |  | D |  | 10285.00 | D | 18.00<sup>(1)</sup> | 0.00 | D |  |
| Common Stock | 2023-02-22 |  | D |  | 250779.00 | D | 18.00<sup>(1)</sup> | 0.00 | I | By Trust<sup>(2)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Options (Right to buy) | $11.47 | 2023-02-22 |  | D |  |  | 10462.00 | <sup>(4)</sup> | 2029-09-18 | Common Stock | 10462.00 | <sup>(3)</sup> | 0.00 | D |  |
| Stock Option (Right to Buy) | $20.55 | 2023-02-22 |  | D |  |  | 984.00 | <sup>(6)</sup> | 2030-04-14 | Common Stock | 984.00 | <sup>(5)</sup> | 0.00 | D |  |
| Stock Option (Right to Buy) | $29.00 | 2023-02-22 |  | D |  |  | 5294.00 | <sup>(6)</sup> | 2030-05-13 | Common Stock | 5294.00 | <sup>(5)</sup> | 0.00 | D |  |
| Stock Option (Right to Buy) | $40.55 | 2023-02-22 |  | D |  |  | 498.00 | <sup>(6)</sup> | 2030-07-14 | Common Stock | 498.00 | <sup>(5)</sup> | 0.00 | D |  |
| Stock Option (Right to Buy) | $30.48 | 2023-02-22 |  | D |  |  | 676.00 | <sup>(6)</sup> | 2030-10-14 | Common Stock | 676.00 | <sup>(5)</sup> | 0.00 | D |  |
| Stock Option (Right to Buy) | $42.68 | 2023-02-22 |  | D |  |  | 483.00 | <sup>(6)</sup> | 2031-01-14 | Common Stock | 483.00 | <sup>(5)</sup> | 0.00 | D |  |
| Stock Option (Right to Buy) | $42.70 | 2023-02-22 |  | D |  |  | 479.00 | <sup>(6)</sup> | 2031-04-14 | Common Stock | 479.00 | <sup>(5)</sup> | 0.00 | D |  |
| Restricted Stock Units | <sup>(7)</sup> | 2023-02-22 |  | D |  |  | 20728.00 | <sup>(8)</sup> | <sup>(8)</sup> | Common Stock | 20728.00 | <sup>(8)</sup> | 0.00 | D |  |

---

### Footnotes:

(1) Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the
"Merger Agreement"), dated as of July 20, 2022, by and among Issuer, Amazon.com, Inc. ("Parent") and Negroni Merger Sub, Inc., a whollyowned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on
February 22, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of Issuercommon stock, par value $0.001 per share ("Shares") issued and outstanding immediately prior to the Effective Time was convertedautomatically into the right to receive $18.00 in cash, without interest (the "Merger Consideration").

(2) Shares held by the Cape Lone Star Trust for which the Reporting Person and his wife are trustees.

(3) Pursuant to the Merger Agreement, at the Effective Time, each outstanding option ("Option") to purchase Shares granted under any of the Issuer's 2007 Equity Incentive Plan, 2017 Equity Incentive Plan, 2020 Equity Incentive Plan and the Iora Third Amended and Restated 2011 Equity Incentive Plan (collective, the "Issuer Stock Plans") or portion thereof that was vested or became vested as of the Effective Time, and had an exercise price per Share that is less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such Option and (ii) the aggregate number of Shares issuable upon exercise of such Option or portion thereof, subject to any required withholding of taxes.

(4) The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the first anniversary of the vesting commencement date; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years, subject to reporting person's continuous service as of each such date. At the Effective Time, any unvested shares subject to the option was accelerated in full.

(5) Pursuant to the Merger Agreement, at the Effective Time, each Option, whether vested or unvested, that has an exercise price per
Share that is greater than the Merger Consideration was canceled without the payment of consideration.

(6) The shares subject to the option are fully vested and immediately exercisable.

(7) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock. RSUs convert into theissuer's common stock on a one-for-one basis.

(8) The RSUs vest on the earlier of (i) the date of the issuer's next annual meeting of stockholders (or the date immediately prior to the next annual meeting of stockholders if the reporting person's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or (ii) the one-year anniversary measured from the date of grant. At the Effective Time, each outstanding RSU that was unvested was accelerated in full and was automatically converted in to the right to receive the Merger Consideration.

**Signature:** /s/ Ivy Tseng, Attorney-in-Fact for David P. Kennedy  
**Date:** 2023-02-24

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**